The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for Celltrion's (KRX:068270) biosimilars Eydenzelt (aflibercept), Stoboclo and Osenvelt (denosumab), and Avtozma (tocilizumab), Celltrion said Monday.
Eydenzelt, comparable to Eylea, targets retinal disorders such as wet AMD and diabetic macular edema. Stoboclo and Osenvelt are at par with Prolia and Xgeva for osteoporosis and cancer-related conditions. Avtozma is comparable to RoActemra for rheumatoid arthritis and other inflammatory diseases, the press release said.
The products require European Commission approval for marketing in the European Union.
Shares of Celltrion rose more than 1% in recent trade on Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。